ABOS vs. CRDF, CMPX, IPSC, XFOR, IPHA, OPT, ADVM, ZURA, CADL, and STRO
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), Century Therapeutics (IPSC), X4 Pharmaceuticals (XFOR), Innate Pharma (IPHA), Opthea (OPT), Adverum Biotechnologies (ADVM), Zura Bio (ZURA), Candel Therapeutics (CADL), and Sutro Biopharma (STRO). These companies are all part of the "biological products, except diagnostic" industry.
Acumen Pharmaceuticals (NASDAQ:ABOS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Cardiff Oncology received 20 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 64.29% of users gave Acumen Pharmaceuticals an outperform vote while only 62.30% of users gave Cardiff Oncology an outperform vote.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,594.92%. Acumen Pharmaceuticals' return on equity of -23.40% beat Cardiff Oncology's return on equity.
In the previous week, Cardiff Oncology had 7 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 12 mentions for Cardiff Oncology and 5 mentions for Acumen Pharmaceuticals. Cardiff Oncology's average media sentiment score of 0.27 beat Acumen Pharmaceuticals' score of 0.26 indicating that Cardiff Oncology is being referred to more favorably in the news media.
Acumen Pharmaceuticals has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 7.5% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 6.3% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cardiff Oncology has higher revenue and earnings than Acumen Pharmaceuticals. Cardiff Oncology is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Acumen Pharmaceuticals presently has a consensus target price of $12.25, indicating a potential upside of 260.29%. Cardiff Oncology has a consensus target price of $10.50, indicating a potential upside of 228.13%. Given Acumen Pharmaceuticals' higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Cardiff Oncology.
Summary
Acumen Pharmaceuticals beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
